Japan Pharmacovigilance Readiness

From the Soseki and Anseki governance structure to EPPV, GVP, and GPSP obligations, Japan’s PV environment demands local expertise that global models often can’t supply alone. Get the guide built to help MAHs operate with confidence.

Download the Guide →

 

Japan remains one of the most strategically important—and regulatorily demanding—markets in global biopharma. Marketing Authorisation Holders must navigate Good Vigilance Practice (GVP), Good Post-Marketing Study Practice (GPSP), the PMD Act, and a distinctive local governance structure that places significant responsibility on in-country safety leadership.

This resource gives PV, regulatory, and quality leaders a clear view of what’s required to operate compliantly in Japan—and where global teams most often encounter friction.

The Japan PV Readiness guide covers:

• Why Japan matters, and what makes its regulatory environment distinct from other major markets
• The local safety governance structure, including the roles of the Marketing Supervisor General (Soseki / 総括製造販売責任者) and Safety Control Manager (Anseki / 安全管理責任者)
• The full scope of post-marketing safety system requirements, from EPPV and risk management to internal inspections, training, and record retention
• The operational challenges MAHs most commonly face—Japanese AE intake, local literature monitoring, EPPV execution—and the compliance risks each one creates
• How PrimeVigilance supports success in Japan through local infrastructure, Japanese-language operations, and flexible specialist resources that complement existing global teams

Whether you’re preparing your first Japanese filing or pressure-testing an existing local setup, this guide gives you the reference framework you need.

Download the guide for a clear breakdown of Japan’s PV requirements—and learn how PrimeVigilance helps MAHs build compliant, scalable safety operations in one of the world’s most rigorous markets.